9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 10

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Maximum tolerated dose,  ,  ,

Interventions: Galinpepimut-S, Nivolumab

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: July 2020

Completion Date: July 2020

Last  Posted Date: July 31, 2019

Location: Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

Website Link: https://ClinicalTrials.gov/show/NCT04040231

Was this article helpful?
Dislike 0